189 related articles for article (PubMed ID: 35051261)
1. An Integrative Morphologic and Molecular Approach for Diagnosis and Subclassification of Rhabdomyosarcoma.
Fan R; Parham DM; Wang LL
Arch Pathol Lab Med; 2022 Aug; 146(8):953-959. PubMed ID: 35051261
[TBL] [Abstract][Full Text] [Related]
2. Rhabdomyosarcoma: Updates on classification and the necessity of molecular testing beyond immunohistochemistry.
Dehner CA; Rudzinski ER; Davis JL
Hum Pathol; 2024 May; 147():72-81. PubMed ID: 38135061
[TBL] [Abstract][Full Text] [Related]
3. The current landscape of rhabdomyosarcomas: an update.
Leiner J; Le Loarer F
Virchows Arch; 2020 Jan; 476(1):97-108. PubMed ID: 31696361
[TBL] [Abstract][Full Text] [Related]
4. Rhabdomyosarcomas in adults and children: an update.
Parham DM; Ellison DA
Arch Pathol Lab Med; 2006 Oct; 130(10):1454-65. PubMed ID: 17090187
[TBL] [Abstract][Full Text] [Related]
5. Evolving classification of rhabdomyosarcoma.
Agaram NP
Histopathology; 2022 Jan; 80(1):98-108. PubMed ID: 34958505
[TBL] [Abstract][Full Text] [Related]
6. Rhabdomyosarcoma: From Obscurity to Clarity in Diagnosis … But With Ongoing Challenges in Management: The Farber-Landing Lecture of 2020.
Parham DM; Giannikopoulos P
Pediatr Dev Pathol; 2021; 24(2):87-95. PubMed ID: 33439112
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic utility of FOXO1 immunohistochemistry for rhabdomyosarcoma classification.
Rutland CD; Gedallovich J; Wang A; Zdravkovic S; Varma S; Hornick JL; Charville GW
Histopathology; 2023 Jul; 83(1):49-56. PubMed ID: 36860202
[TBL] [Abstract][Full Text] [Related]
8. Pathologic classification of rhabdomyosarcomas and correlations with molecular studies.
Parham DM
Mod Pathol; 2001 May; 14(5):506-14. PubMed ID: 11353062
[TBL] [Abstract][Full Text] [Related]
9. Sclerosing rhabdomyosarcoma in childhood: case report and review of the literature.
Vadgama B; Sebire NJ; Malone M; Ramsay AD
Pediatr Dev Pathol; 2004; 7(4):391-6. PubMed ID: 15383934
[TBL] [Abstract][Full Text] [Related]
10. Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe.
Hettmer S; Linardic CM; Kelsey A; Rudzinski ER; Vokuhl C; Selfe J; Ruhen O; Shern JF; Khan J; Kovach AR; Lupo PJ; Gatz SA; Schäfer BW; Volchenboum S; Minard-Colin V; Koscielniak E; Hawkins DS; Bisogno G; Sparber-Sauer M; Venkatramani R; Merks JHM; Shipley J
Eur J Cancer; 2022 Sep; 172():367-386. PubMed ID: 35839732
[TBL] [Abstract][Full Text] [Related]
11. [Spindle cell rhabdomyosarcoma in adults: a new entity in the spectrum of malignant mesenchymal tumors of soft tissues].
Mentzel T
Pathologe; 2010 Mar; 31(2):91-6. PubMed ID: 19997735
[TBL] [Abstract][Full Text] [Related]
12. Complete mimicry: Rhabdomyosarcoma with FUS::TFCP2 fusion masquerading as carcinoma-diagnostic challenge and report of two cases.
Carrillo-Ng H; Liang Y; Chang S; Afkhami M; Gernon T; Bell D; Arias-Stella JA
Genes Chromosomes Cancer; 2023 Jul; 62(7):430-436. PubMed ID: 37057803
[TBL] [Abstract][Full Text] [Related]
13. A clinicopathologic study of head and neck rhabdomyosarcomas showing FOXO1 fusion-positive alveolar and MYOD1-mutant sclerosing are associated with unfavorable outcome.
Owosho AA; Huang SC; Chen S; Kashikar S; Estilo CL; Wolden SL; Wexler LH; Huryn JM; Antonescu CR
Oral Oncol; 2016 Oct; 61():89-97. PubMed ID: 27688110
[TBL] [Abstract][Full Text] [Related]
14. Spindle Cell/Sclerosing Rhabdomyosarcoma With
Rakheja D; Park JY; Alhasan M; Uddin N
Int J Surg Pathol; 2022 Dec; 30(8):950-955. PubMed ID: 35466752
[TBL] [Abstract][Full Text] [Related]
15. Genetic Characterization, Current Model Systems and Prognostic Stratification in PAX Fusion-Negative vs. PAX Fusion-Positive Rhabdomyosarcoma.
Dehner CA; Armstrong AE; Yohe M; Shern JF; Hirbe AC
Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680895
[TBL] [Abstract][Full Text] [Related]
16. Adult sclerosing rhabdomyosarcoma: cytogenetic link with embryonal rhabdomyosarcoma.
Croes R; Debiec-Rychter M; Cokelaere K; De Vos R; Hagemeijer A; Sciot R
Virchows Arch; 2005 Jan; 446(1):64-7. PubMed ID: 15660283
[TBL] [Abstract][Full Text] [Related]
17. Recurrent MYOD1 mutations in pediatric and adult sclerosing and spindle cell rhabdomyosarcomas: evidence for a common pathogenesis.
Agaram NP; Chen CL; Zhang L; LaQuaglia MP; Wexler L; Antonescu CR
Genes Chromosomes Cancer; 2014 Sep; 53(9):779-87. PubMed ID: 24824843
[TBL] [Abstract][Full Text] [Related]
18. Genomic analysis and preclinical xenograft model development identify potential therapeutic targets for MYOD1-mutant soft-tissue sarcoma of childhood.
Ting MA; Reuther J; Chandramohan R; Voicu H; Gandhi I; Liu M; Cortes-Santiago N; Foster JH; Hicks J; Nuchtern J; Scollon S; Plon SE; Chintagumpala M; Rainusso N; Roy A; Parsons DW
J Pathol; 2021 Sep; 255(1):52-61. PubMed ID: 34086347
[TBL] [Abstract][Full Text] [Related]
19. Soft Tissue Special Issue: Skeletal Muscle Tumors: A Clinicopathological Review.
Kohashi K; Kinoshita I; Oda Y
Head Neck Pathol; 2020 Mar; 14(1):12-20. PubMed ID: 31950473
[TBL] [Abstract][Full Text] [Related]
20. Intraosseous Spindle Cell/Epithelioid Rhabdomyosarcoma with
Valério E; Furtado Costa JL; Perez Fraile NM; Credidio CH; Taveira Garcia MR; Neto CS; Costa FD
Int J Surg Pathol; 2023 Aug; 31(5):861-865. PubMed ID: 36474403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
